UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 28, 2021
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-39202 | 26-2540421 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
(Address of Principal Executive Offices, and Zip Code)
(610) 727-3913
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.0001 per share | ANVS | NYSE American |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 7.01 | Regulation FD Disclosure. |
On July 28, 2021, as part of the Alzheimer’s Association International Conference (“AAIC”), Annovis Bio, Inc. (the “Company”) will be presenting new clinical efficacy and biomarker data of its drug ANVS401 during a panel presentation. A copy of the presentation is furnished as Exhibit 99.1.
The information in this Item 7.01, including the attached exhibit, is furnished solely pursuant to Item 7.01 of Form 8-K. Consequently, such information is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Further, the information in this Item 7.01, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.
Cautionary Statement Regarding Forward-Looking Information
This current report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than those of historical fact in this presentation and accompanying oral commentary are forward-looking statements. Forward-looking statements may be identified by terminology such as “believe,” “anticipate,” “plan,” “may,” “intend,” “will,” “should,” “expect,” “estimate,” “potential” and “continue” and similar expressions, including the negative of these words, but not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding the Company’s expectations regarding projected timelines of clinical trials, and expectations regarding current or future clinical trials. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including the timing of clinical trials. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) and elsewhere in our filings and reports with the SEC. These risks, uncertainties and other factors may cause our actual results to differ materially and adversely from what is contained in (or may be implied from) any forward-looking statements. Forward-looking statements speak as of the date they are made, and the Company undertakes no obligation to update them except as may be required under applicable law.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit
No. |
Description | |
99.1 | AAIC Panel Presentation dated July 28, 2021 (furnished herewith) | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANNOVIS BIO, INC. | ||
Date: July 28, 2021 | By: |
/s/ Jeffrey McGroarty |
Name: Jeffrey McGroarty | ||
Title: Chief Financial Officer |
Exhibit 99.1
AAIC Panel July 28, 2021 Symbol: ANVS (NYSE American)
NEUROTOXIC PROTEINS IMPAIR AXONAL TRANSPORT AND CAUSE A TOXIC CASCADE Posiphen IMPROVES AXONAL TRANSPORT AND IMPEDES THE TOXIC CASCADE IMPAIRED AXONAL TRANSPORT SLOWER SYNAPTIC TRANSMISSION INFLAMMATION DEATH OF NERVE CELLS LOSS OF COGNITIVE AND MOTOR FUNCTION IMPROVED AXONAL TRANSPORT INCREASED SYNAPTIC TRANSMISSION NO INFLAMMATION HEALTHY NERVE CELLS IMPROVED COGNITIVE AND MOTOR FUNCTION HIGH LEVELS OF NEUROTOXIC PROTEINS Posiphen LOWERS LEVELS OF NEUROTOXIC PROTEINS
3 TWO PHASE 2 CLINICAL TRIALS AD Trial PD Trial Therapeutic Area Early to Moderate AD Early to Moderate PD Patients 14 14 + 40 Phase 2 Sites 12 Country United States Design Double - Blind, Placebo - Controlled, Biomarker Study Endpoints Reversal of Toxic Cascade Exploratory Efficacy
TIMELINE OF PHASE 2 CLINICAL TRIAL IN AD AND PD Start Up AD/PD Study August 2020 June/July 2021 September 2021 4 AD & PD Markers AD & PD Efficacy Whole Study May 2021 Efficacy and biomarker d ata as of July 2021. Additional markers in CSF and plasma are still being measured A meeting with the FDA to discuss the data from the AD and the PD study as well as from the chronic toxicology in rats and dogs is projected for Fall of 2021 January 2020
REVERSAL OF TOXIC CASCADE EXPECTED OUTCOME ACTUAL OUTCOME AD PD Neurotoxic proteins Axonal transport Axonal damage Inflammation Synaptic Markers Control proteins 0 Efficacy: WAIS coding Efficacy: Motor function Efficacy: Cognition REVERSAL OF TOXIC CASCADE: EFFICACY Data from first 14 AD and 14 PD patients 5
ALZHEIMER PARKINSON Patients Enrolled Placebo (N=6) Posiphen 80mg (N=10) Total (N=16) Placebo (N=5) Posiphen 80mg (N=10) Total (N=15) Age (years) 68.0 ( 6.87) 72.8 ( 6.34) 71.0 ( 6.75) 75.4 ( 3.13) 65.0 ( 9.31) 68.5 ( 9.18) Male 3 ( 50.0%) 2 ( 20.0%) 5 ( 31.3%) 3 ( 60.0%) 8 ( 80.0%) 11 ( 73.3%) Female 3 ( 50.0%) 8 ( 80.0%) 11 ( 68.8%) 2 ( 40.0%) 2 ( 20.0%) 4 ( 26.7%) HISPANIC 4 ( 66.7%) 5 ( 50.0%) 9 ( 56.3%) 2 ( 40.0%) 0 ( 0.0%) 2 ( 13.3%) CAUCASIAN 2 ( 33.3%) 5 ( 50.0%) 7 ( 43.8%) 3 ( 60.0%) 10 (100.0%) 13 ( 86.7%) WHITE 4 ( 66.7%) 8 ( 80.0%) 12 ( 75.0%) 5 (100.0%) 10 (100.0%) 15 (100.0%) AFRICAN AMERICAN 1 ( 16.7%) 0 ( 0.0%) 1 ( 6.3%) 0 0 0 ASIAN 1 ( 16.7%) 1 ( 10.0%) 2 ( 12.5%) 0 0 0 NATIVE HAWAIIAN 0 ( 0.0%) 1 ( 10.0%) 1 ( 6.3%) 0 0 0 BASELINE DEMOGRAPHICS
EFFICACY IN AD PATIENTS – ADAS - Cog11 D ata from 14 AD patients 7 Left: From baseline to 25 days in the Posiphen - treated group, ADAS - Cog11 improved by 4.4 points, a statistically significant improvement of 30% (p < 0.05). Right: Posiphen - treated group compared to placebo group at baseline and 25 days showed an improvement of 3.3 points, or 22% (p= 0.13). BETTER 100% 70% 100% 92% 70% 60% 65% 70% 75% 80% 85% 90% 95% 100% 105% Posiphen day 0 Posiphen day 25 Placebo day 0 Placebo day 25 Posiphen day 25 % ADAS - Cog11 *
EFFICACY IN AD PATIENTS – ADAS - Cogs11 Data from 14 AD patients 0.5 0.6 0.7 0.8 0.9 1 1.1 ADAS-COG3 ADAS-COG6 ADAS-COG11 ADAS-COG14 ADAS COGs %Placebo %Posiphen Posiphen - treated group showed trends of improvement in all four ADAS - Cog tests performed compared to placebo group. 8
EFFICACY IN PD PATIENTS – MDS - UPDRS TEST Data from 14 PD patients -30% -25% -20% -15% -10% -5% 0% 5% 10% 15% Part1 Part2 Part3 Part4 Total UPDRS Placebo Posiphen Posiphen - treated group showed trends of improvement in all four parts of UPDRS test compared to placebo group. 9
EFFICACY IN AD AND PD PATIENTS – WAIS CODING TEST D ata from 14 AD and 14 PD patients This is the first double - blind, placebo - controlled study that shows cognitive improvements in AD patients as measured by ADAS - Cog and functional improvements in PD patients as measured by the Unified Parkinson's Disease Rating Scale (UPDRS). The WAIS coding test measures speed in movement and thinking. Treated AD patients show a 6.6 point and PD patients a 6.1 - point improvement in coding after Posiphen treatment. 10 100% 123% 100% 107% 123% 90% 95% 100% 105% 110% 115% 120% 125% Posiphen day 0 Posiphen day 25 Placebo day 0 Placebo day 25 Posiphen day 25 % of correct items_AD 100% 114% 100% 90% 114% 80% 85% 90% 95% 100% 105% 110% 115% 120% Posiphen day 0 Posiphen day 25 Placebo day 0 Placebo day 25 Posiphen day 25 % of correct items_PD * * *
EFFICACY IN AD AND PD PATIENTS - MMSE 11 While there is a positive trend in AD, the changes in MMSE are not statistically significant. MMSE AD PD Placebo Posiphen Placebo Posiphen MMSE Baseline 24.5 25.4 27.6 29.1 25 Days later 25.7 26.2 28.0 29.1 Improvement in MMSE 1.2 0.8 0.4 0.0
EFFICACY IN AD PATIENTS – CDR – SUM OF BOXES 12 In AD patients there are positive trends in orientation, judgement and problem solving, home and hobbies as well as total CDR score, but the data is not statistically significant. CDR Placebo Posiphen Improvement in total score - 1.17 - 0.96
SAFETY SUMMARY 13 AD Patients PD Patients Placebo (N=6) Posiphen 80mg (N=10) Total (N=16) Placebo (N=5) Posiphen 80mg (N=10) Total (N=15) Subjects with any AEs 3 (50.0%) 5 (50.0%) 8 (50.0%) 3 (60.0%) 3 (30.0%) 6 (40.0%) Number of AEs 4 7 11 5 3 8 Serious AEs 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) AEs that led to Drug Interrupted 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) AEs that led to Drug Withdrawn 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) AEs Suspected Drug Related 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (20.0%) 0 (0.0%) 1 (6.7%) AEs Study Procedure 3 (50.0%) 4 (40.0%) 7 (43.8%) 2 (40.0%) 1 (10.0%) 3 (20.0%) CTCAE Grade 1 3 (50.0%) 4 (40.0%) 7 (43.8%) 3 (60.0%) 3 (30.0%) 6 (40.0%) CTCAE Grade 2 0 (0.0%) 1 (10.0%) 1 (6.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Most AEs were due to the spinal fluid extraction that resulted in headaches and back aches Data from first 14 AD and PD patients
REVERSAL OF TOXIC CASCADE EXPECTED OUTCOME ACTUAL OUTCOME AD PD Neurotoxic proteins Axonal transport Axonal damage Inflammation Synaptic Markers Control proteins 0 Efficacy: WAIS coding Efficacy: Motor function Efficacy: Cognition REVERSAL OF TOXIC CASCADE: MARKERS D ata from first 14 AD and 14 PD patients 14
STEP ONE OF TOXIC CASCADE NEUROTOXIC PROTEIN S ARE LOWERED Data from first 14 AD and PD patients - 14.00% - 12.00% - 10.00% - 8.00% - 6.00% - 4.00% - 2.00% 0.00% 2.00% 4.00% Ab40 Ab42 sAPPa sAPPb P - Tau T - Tau % difference Posiphen vs Placebo_AD T - Tau -14.00% -12.00% -10.00% -8.00% -6.00% -4.00% -2.00% 0.00% 2.00% 4.00% Ab40 Ab42 sAPPa sAPPb P-Tau T-Tau % difference Posiphen vs Placebo_PD sAPPb T - Tau * 15
A β 42/A β 40 RATIO IN AD AND PD PATIENTS Data from first 14 AD and PD patients 16 AD Patients PD Patients Placebo Posiphen Placebo Posiphen Baseline 0.064 0.059 0.083 0.097 25 Days 0.064 0.062 0.083 0.097 p - Value 0.0113 The A β 42/A β 40 is < 0.072 in AD. Our ratios in fact show that AD patients have AD, while PD patients do not. It also shows that in ANVS401 treated patients one month of treatment improves the ratio in a statistically significant fashion.
STEP TWO OF TOXIC CASCADE NEUROFILAMENT LIGHT IS LOWERED IN AD AND PD PATIENTS Data from first 14 AD and PD patients 17 -14% -12% -10% -8% -6% -4% -2% 0% AD PD % Difference Posiphen vs. Placebo Neurofilament light represents the health of the axon and neuron. In both Posiphen - treated patient populations, NfL is reduced representing better axonal health.
STEP THREE OF TOXIC CASCADE INFLAMMATION IS LOWER IN PD PATIENTS Data from first 14 PD patients 18 The trial measured four inflammatory markers that are prevalent in the brains of AD and of PD patients. Each of the inflammatory markers showed statistically significant reduction after 25 days of treatment with ANVS401 compared to baseline and compared to placebo. Inflammatory Marker Compared to Baseline or Placebo % Change from Baseline or Placebo p - Value YKL40 within - 22.9 0.032 between - 55.5 0.097 sTREM2 within - 17.1 0.0001 between - 42.7 0.001 GFAp within - 41.6 0.000001 between - 28.4 0.013
19 WORK IN PROGRESS & SUMMARY • We have finished treating the additional 40 PD patients and are expecting to complete all the biomarkers of the toxic cascade in the next two months. • The reversal of the toxic cascade confirms and cements the data seen to date. • Showing efficacy in AD and in PD patients by two different tests each and showing that the efficacy spans all areas of the ADAS - Cog and the UPDRS strengthens our conclusion that Posiphen is effective in both patient populations.
THANK YOU Symbol: ANVS (NYSE American)